aflibercept works in treating patients with stage III or stage IV melanoma that cannot be
removed by surgery. Aldesleukin may stimulate the white blood cells to kill cancer.
Aflibercept may stop the growth of melanoma by blocking blood flow to the tumor. It is not
yet known whether aldesleukin is more effective with or without aflibercept in treating
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: firstname.lastname@example.org
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.